Palbociclib and sunitinib for advanced solid tumors
Treatments studied
Part of Cancer clinical trials.
This study tests a combination of two oral drugs—palbociclib and sunitinib—for people with advanced solid tumors that have not responded to other treatments. The goal is to see if these drugs together can help shrink or slow the growth of the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have an advanced solid tumor (like stomach, ovarian, breast, lung, colon, bile duct, pancreas, sarcoma, or another type) that has spread or can't be removed, and you have tried or refused other treatments.
- You are able to get out of bed and take care of yourself most of the day (ECOG 0-2).
- Your blood tests show good bone marrow, kidney, and liver function.
- You are not pregnant or breastfeeding, and you agree to use effective birth control if needed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two drugs, ulixertinib and palbociclib, taken together to see if they can shrink tumors in patients with advanced pancreatic cancer, melanoma, or other solid tumors. It may be an option for people who have already tried standard treatments.
This trial tests two pills (pazopanib and palbociclib) together for people with advanced solid tumors that have a specific gene change (11q13 amplification) and have stopped responding to other treatments. The goal is to see if this combination can shrink tumors or slow their growth.
This trial tests a combination of two experimental drugs, Simmitinib and SG001, in people with advanced solid tumors that have stopped responding to standard treatments. It aims to find out if this combination is safe and effective.
This trial tests a combination of three drugs (Ipalotinib, Sunitinib, and Olaparib) given before surgery to shrink tumors in people with a specific type of advanced ovarian cancer that has a genetic marker called HRD-positive. The goal is to see if this treatment helps make surgery more effective.
This trial tests a drug called palbociclib for people with advanced liver cancer who have already tried at least two other treatments. The goal is to see if palbociclib can help shrink the cancer or slow its growth.
This study tests a combination of two medicines—palbociclib and sasanlimab—in people with advanced clear cell or papillary kidney cancer. It’s mainly designed to check safety (and early signs of how well the treatment may work) in these cancer types.
Hear when a new Solid Tumors Refractory to Standard Therapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.